title: Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma.
authors.affiliation: a Division of Medical Oncology , National Cancer Centre Singapore , Singapore.
authors.forename: Joycelyn J X
authors.initials: JJ
authors.lastname: Lee
authors.affiliation: b Department of Pharmacy , National Cancer Centre Singapore , Singapore.|c Department of Pharmacy , National University of Singapore , Singapore.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
authors.affiliation: a Division of Medical Oncology , National Cancer Centre Singapore , Singapore.
authors.forename: Tiffany
authors.initials: T
authors.lastname: Tang
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D058990:Molecular Targeted Therapy; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification / Q000472:pathogenicity; D009364:Neoplasm Recurrence, Local; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D014057:Tomography, X-Ray Computed; D014376:Tuberculosis / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000995:Antitubercular Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab